REQUEST A DEMO
Total
USD $0.00
Search more companies

China Sxt Pharmaceuticals Inc. (China)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: China Sxt Pharmaceuticals Inc. Profile Updated: November 20, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

The Company, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The Company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The Company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
HISTORY
2017 - The Company is a holding company incorporated in British Virgin Islands on July 4, 2017. The Company is headquartered in Taizhou, China.
- On July 21, 2017, the Company wholly owned subsidiary China SXT Group Limited (“SXT HK”) was incorporated in Hong Kong.
2019 On January 3, 2019, The Company s ordinary shares commenced trading on the Nasdaq Capital Market under the symbol of “SXTC.”

Headquarters
178 Taidong Rd North
Taizhou; Zhejiang; Postal Code: 225300

Contact Details: Purchase the China Sxt Pharmaceuticals Inc. report to view the information.

Website: http://www.sxtchina.com

Basic Information
Total Employees:
Purchase the China Sxt Pharmaceuticals Inc. report to view the information.
Outstanding Shares:
Purchase the China Sxt Pharmaceuticals Inc. report to view the information.
Financial Auditors:
Purchase the China Sxt Pharmaceuticals Inc. report to view the information.
Incorporation Date:
2017
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Financial Officer
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Outside Director
Ownership Details
Purchase this report to view the information.
12.19%
Purchase this report to view the information.
11.5%
Purchase this report to view the information.
4.47%
Subsidiaries
China Sxt Group Limited (Hong Kong SAR, China)
Jiangsu Su Xuan Tang Pharmaceutical Co. Ltd.
Taizhou Su Xuan Tang Biotechnology, Co. Ltd.
Company Performance
Financial values in the chart are available after China Sxt Pharmaceuticals Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
-2.23%
Total operating revenue
-2.23%
Operating profit (EBIT)
53.19%
EBITDA
64.72%
Net Profit (Loss) for the Period
47.78%
Total assets
-21.75%
Total equity
-5.18%
Operating Profit Margin (ROS)
144.25%
Net Profit Margin
140.22%
Return on Equity (ROE)
18.15%
Debt to Equity Ratio
-6.17%
Quick Ratio
0.2%
Cash Ratio
0.16%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?